Long-term safety of NT-501 implant for MacTel type 2
Part of Eyes & vision clinical trials.
This study checks the long-term safety and effectiveness of the NT-501 implant for people with MacTel type 2. It is for people who have already been in an earlier NT-501 study, whether they got the real implant or a sham procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already taken part in a clinical study for NT-501 (the implant for MacTel).
- If you had the real NT-501 implant in a Phase 3 study, you must still have at least one implant in your eye.
- If you had the real implant in an earlier Phase 1 or Phase 2 study, you must still have at least one implant.
- If you received a sham (placebo) procedure in a Phase 3 study, you can join a new group that will receive the real implant.
- Women who can get pregnant must use highly effective birth control (like an IUD, implant, or abstinence) if they are in the sham-to-implant group.
- You cannot have any serious eye problems (like glaucoma, diabetic retinopathy, or certain lens opacities) that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking L-serine supplements can help protect vision in people with MacTel type 2, a rare eye disease. It may slow vision loss by addressing metabolic issues in the retina.
This study tests a device that is surgically implanted in the eye of people with late-stage age-related macular degeneration (AMD). It also uses vision training with a telescope-like tool to see if the treatment can improve day-to-day vision.
This study is an extension of a previous trial (study 301) for adults with a heart condition called transthyretin amyloid cardiomyopathy. It aims to evaluate the long-term safety and effectiveness of an investigational drug (ALXN2220). Participants who completed the earlier study without stopping the drug or withdrawing consent may be eligible to continue receiving the treatment.
This trial tests whether KB801 can help heal persistent corneal defects better than a placebo. It is for people with neurotrophic keratitis (a condition where the cornea loses sensation) that has not improved with standard care.
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
This post-market study looks at how well a telescope-like eye implant (NG SI IMT 3X) works for people with very advanced age-related macular degeneration that affects the center of vision, plus cataracts. The implant is placed in one eye, and you’ll get training to learn how to use it after surgery.
Hear when a new Macular Telangiectasia Type 2 (MacTel) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.